ArticleVirology journal2026
Inhibitory effect of three components derived from Salvia miltiorrhiza against human cytomegalovirus.
Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundHuman cytomegalovirus (HCMV) infection is responsible for congenital infections and poses a significant health risk to immunocompromised individuals. To date, there is no effective HCMV vaccine. Salvia miltiorrhiza is a well-known traditional Chinese herb that possesses active pharmacological effects including antiviral activity. However, no studies on the effects of Salvia miltiorrhiza on HCMV have been reported thus far.
methodsFirstly, the cytotoxicity of five active components derived from Salvia miltiorrhiza was screened, then morphology, western blotting, qPCR, indirect immunofluorescence assay (IFA) and TCID
resultsSalvianolic acid B, Tanshinone ⅡA, and Cryptotanshinone derived from Salvia miltiorrhiza were found to prevent lytic cytopathic changes, inhibit the expression of viral proteins, suppress the replication of HCMV DNA, and significantly reduce the viral titer in WI-38 cells. Time-of-addition experiments showed that they predominantly act during the Post-entry treatment (Post-T) stage. Moreover, they effectively suppressed HCMV-induced cellular senescence, which was evidenced by a decline in senescence-associated β-galactosidase activity, alleviated senescence-associated heterochromatin foci (SAHF), reduced expression of p16, p21, and p53, and decreased production of reactive oxygen species (ROS).
conclusionTo our knowledge, this is the first report that salvianolic acid B, tanshinone IIA, and cryptotanshinone derived from Salvia miltiorrhiza exhibit anti-HCMV activity in vitro, and suggest potential for further development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.